Following hematopoietic SCT (HSCT) for non-malignant disorders (NMDs) variable donor chimerism among lympho-hematopoietic lines may be observed. We retrospectively evaluated early post-HSCT, lineage-sorted (CD3 þ and CD15 þ ) peripheral blood leukocyte chimerism data to characterize patterns and assess for association with long-term CD15 þ engraftment. 'Early' was defined as the first value obtained between days þ 14 and þ 42, 'late' as the last recorded value after day þ 90. 'High' donor chimerism was defined as X80% on either fraction at all time-points. Patients were classified into four subgroups with respect to early CD3 þ /CD15 þ chimerism patterns (high/low) then analyzed for long-term CD15 þ chimerism status. A total of 135 transplants were evaluable, with all three time-points available in 97. Underlying disease, graft source, patient age and conditioning intensity varied. 'Split' early chimerism (discordant high/low CD3 þ /CD15 þ status) was common. Multivariable analysis revealed strong association between conditioning regimen and primary disease on early CD3 þ /CD15 þ chimerism patterns and a dominant predictive effect of early CD15 þ chimerism on long-term CD15 þ donor engraftment (observed at median day þ 365). These data may guide real-time clinician decisions (restraint vs intervention, when available) when faced with unfavorable or unusual early lympho-hematopoietic chimerism patterns following HSCT for NMD.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) is an increasingly applied therapy for non-malignant disease (NMD). [1] [2] [3] [4] [5] [6] [7] According to data from the Center for International Blood and Marrow Transplant Research, at least 2710 patients received a first allogeneic HSCT in the United States alone for a NMD from 2008 through 2011 (CIBMTR, unpublished data). In contrast to HSCT for malignant disorders, mixed donor/recipient lympho-hematopoietic chimerism following NMD HSCT is commonly observed, particularly in the immediate post-transplant period. For NMD patients, this phenomenon is likely due in part to higher engraftment barriers and the prevalent use of less-intense conditioning regimens. Ultimately, the success of HSCT for NMD may depend on the degree of long-term, donor-derived hematopoiesis for correction of the underlying metabolic, immune or hematopoietic defect. [8] [9] [10] [11] [12] Peripheral blood leukocytes (PBL), instead of marrow, are commonly monitored for donor lympho-hematopoietic chimerism post-HSCT for NMD. In accordance with published recommendations from the American Society of Blood and Marrow Transplantation and International Bone Marrow Transplant Registry, many centers favor post-HSCT fractionated PBL chimerism monitoring for its convenience, minimal risk and informative power. 13 However, in the immediate post-transplant period, incomplete and variable donor chimerism among lympho-hematopoietic lines may be observed. This variability can be anxiety provoking for both the patient and the clinician. We aimed to determine early chimerism patterns of T-lymphoid (CD3 þ ) and myelo-monocytic (CD15 þ ) PBL fractions, as well as the prognostic significance of these patterns with respect to long-term donor engraftment following HSCT for NMD.
MATERIALS AND METHODS

Cohort determination and transplant procedure
All allogeneic HSCT for NMD at the University of Minnesota from May 2009 through August 2012 were identified. Transplants were as per an Institutional Review Board-approved protocol following provision of informed consent. Protocol assignment was based on the patient's primary disorder, available allograft source(s) and/or the discretion of the treating physician. Allograft matching was as per institutional criteria: related and unrelated donor grafts, genotypic determination at HLA-A, -B, -C and -DRB1; umbilical cord blood grafts, phenotypic determination at HLA-A and -B and genotypic determination at HLA-DRB1. Supportive care (including GVHD prophylaxis, anti-infective therapies, blood product support and growth factor support) was per the transplant protocol and/or the University of Minnesota Blood and Marrow Transplant Program Guidelines. Patient and transplant-related data were obtained from the prospectively maintained University of Minnesota Blood and Marrow Transplant Database and from retrospective review of patient medical records.
Exclusion criteria
Transplants were excluded from analysis for the following reasons: (i) double umbilical cord blood allograft; (ii) demonstration of prolonged (442 days) neutropenic aplasia (ANCo500/mL) post-HSCT; (iii) a prior HSCT within 1 year of transplant; or (iv) lack of evaluable post-HSCT chimerism data. 1 Internal Medicine/Pediatrics, University of Minnesota, Minneapolis, MN, USA; CD3 þ and CD15 þ PBL chimerism analysis Whole blood was collected for donor chimerism assessment at varying time-points according to the patient's primary HSCT protocol. Assays were performed by our clinical hospital laboratory. Sorted T-lymphoid and myelo-monocytic fractions were generated with X98% purity by positive immunomagnetic selection of the CD3 þ and CD15 þ populations, respectively. Donor chimerism values on each fraction were achieved by PCR amplification of donor-specific short tandem nucleotide repeats. Absolute leukocyte subset values at the time of chimerism analysis were obtained by review of routine hemogram with leukocyte differential results. The sum of absolute monocyte and neutrophil counts was used to assess correlation with early CD15 þ chimerism values, whereas the absolute lymphocyte count (in the absence of absolute T-cell-specific data) was used to assess correlation with early CD3 þ chimerism values.
Definitions
For each transplant, 'early' chimerism values were defined as the first recorded between days þ 14 and þ 42. 'Late CD15 þ ' chimerism values were defined as the latest recorded Xday þ 90. For patients undergoing repeat HSCT before day þ 90 (n ¼ 6), 'late CD15 þ ' donor chimerism was set to 0% at day 365 (the median time of observation for the cohort). For patients receiving DLI, chimerism values were considered valid until the date of first DLI.
If an early CD3 þ or CD15 þ value demonstrated X80% donor chimerism, it was labeled 'high'; otherwise, it was assigned 'low.' Longterm engraftment was considered 'successful' if late CD15 þ evaluation demonstrated X80% donor chimerism.
Statistical analysis
Statistical models were used to explore relationships among early CD3 þ / CD15 þ donor chimerism, patient and transplant-related factors, and successful long-term engraftment. Fisher's exact test was used for twofactor associations and multivariable logistic regression modeled the effects of multiple factors on the odds of success. Owing to small sample size and skewed chimerism distributions, CD3 þ and CD15 þ values were treated as binary variables as defined before. The degree of correlation between early lineage-specific chimerism values and synchronous absolute count of respective leukocyte subsets was assessed.
RESULTS
Cohort description A total of 162 transplants for NMD occurred between May 2009
and August 2013 at the University of Minnesota; 27 were excluded from analysis (14 for double umbilical cord blood; 9 for prolonged neutropenic aplasia; 3 for prior HSCT within a year of the transplant; and 1 for lack of evaluable chimerism data). For patient and transplant-related characteristics, see Table 1 .
Early CD3 þ donor chimerism A valid early CD3 þ reading was available for 110 transplants with median donor chimerism 88%; 42 readings (38%) were classified as low. Conditioning intensity correlated significantly with early CD3 þ high/low status: after reduced-intensity conditioning (RIC), 51% (21 of 41) demonstrated low early CD3 þ chimerism compared with 30% (21 of 69) after myeloablative (MA) conditioning (multivariable logistic regression Po0.01). Early CD3 þ chimerism values did not correlate with synchronous absolute lymphocyte counts (r ¼ 0.14). Neither graft source, donor/recipient HLA matching, underlying disease nor patient age correlated with early CD3 þ chimerism status.
Early CD15 þ donor chimerism A valid early CD15 þ reading was available for 113 transplants; 19 patients (17%) were classified as low and 69 patients (61%) achieved 100% early CD15 þ donor engraftment. Conditioning intensity correlated significantly with early CD15 þ high/low status, with low chimerism seen more commonly following RIC (36% vs 6% for MA, multivariable logistic regression Po0.001).
Patients with Fanconi anemia (FA)/other marrow failure were very likely to demonstrate high early CD15 þ chimerism (36 of 37, or 97%). All FA patients underwent MA conditioning; however, of 12 marrow failure patients with other (non-FA) causes who underwent RIC, all (100%) still demonstrated high early CD15 þ . For the entire cohort, early CD15 þ chimerism values did not correlate with the synchronous sum of absolute neutrophils and monocytes (r ¼ À 0.06). Neither graft source, donor/recipient HLA matching, nor patient age correlated with early CD15 þ chimerism status. Late Cd15 þ donor chimerism A valid late CD15 þ reading was available for 120 patients at a median day þ 365 (range, days þ 91 to þ 809); 17 (14%) were classified as 'failed' (o 80%) donor and 86 (72%) achieved 100% late CD15 þ donor engraftment.
The correlation between subgroup assignment by early CD3 þ / CD15 þ chimerism pattern and long-term CD15 þ chimerism (success vs failure) was as follows: high3/high15, 8% failure (5/60), low3/high15, 4% failure (1/23), high3/low15, 0% failure (0/2) and low3/low15, 83% failure (10/12) (see Figure 1) . In a two-factor multivariable logistic regression, low early CD15 þ status was independently associated with long-term failure (Po0.0001), but low early CD3 þ status was not after controlling for early CD15 þ status (P ¼ 0.53).
Owing to the high correlation between early and late CD15 þ chimerism values, factors that were predictive of early CD15 þ Early CD3/CD15 correlation with long-term engraftment TG Ketterl et al status were likewise predictive of late CD15 þ status. Failure was associated with conditioning intensity (6% for MA vs 29% for RIC, Po0.01) and diagnosis (2% for FA/other marrow failure vs 21% for other diagnoses, P ¼ 0.03). Neither graft source, donor/recipient HLA status nor patient age was associated with long-term CD15 þ chimerism status. Conditioning strongly influenced the relationship between early and late chimerism. MA recipients were very likely to have high early and high late CD15 þ status, despite variable early CD3 þ , which amounted to weak correlation between early CD3 þ and CD15 þ chimerism values in this group (r ¼ 0.2). In contrast, RIC recipients had more variable early CD15 þ values that correlated highly with early CD3 þ values (r ¼ 0.8).
DISCUSSION
Incomplete donor engraftment is commonly observed after HSCT for NMD, particularly in the immediate post-transplant period. Although complete long-term engraftment may not be necessary for amelioration of disease, some degree of donor-derived hematopoiesis remains central to 'success' for correction of the underlying hematopoietic, immunologic or metabolic defect.
Here we report a large, single-center, diverse patient cohort treated with HSCT for a myriad of underlying NMD. Our data show significant variability in early donor chimerism on fractionated PBL populations. Overall, 38% demonstrated 'low' early donor presence in the T-lymphoid (CD3 þ ) compartment, defined as o80% chimerism. Among recipients of RIC regimens, this fraction increased to 51%. Similarly, 17% of the entire cohort had 'low' (o80% donor) early myelo-monocytic (CD15 þ ) chimerism. Among RIC recipients, this percentage increased to 36%. Furthermore, a 'split' readout between early CD3 þ /CD15 þ engraftment status (high/low or low/high) occurred in 28 (26%) of the cohort.
Such variability can provoke anxiety in patients and clinicians with respect to long-term engraftment. Therefore, we aimed to determine if patterns of early lineage-specific chimerism could portend long-term engraftment in this NMD population. Our analysis reveals several findings: (i) early CD15 þ chimerism status (but not early CD3 þ chimerism status) is a significant, dominant and independent predictor of long-term CD15 þ engraftment; (ii) for patients with low early CD15 þ donor chimerism, the synchronous presence of higher CD3 þ donor chimerism is associated with a trend toward favorable long-term CD15 þ engraftment; (iii) for patients with low early CD3 þ donor chimerism, synchronous high donor CD15 þ presence appears 'protective' and to strongly predict favorable long-term CD15 þ engraftment; and (iv) following RIC regimens, when greater variability in early CD3 þ /CD15 þ patterns was observed, early CD15 þ status remains the dominant predictor of long-term CD15 þ chimerism.
Not surprisingly, a large percentage of patients in this NMD cohort were conditioned with RIC (39%) and conditioning regimen intensity predicted both early and late CD15 þ chimerism status. Among evaluable RIC transplants, greater correlation between early CD15 þ and CD3 þ values was observed. Still, in this RIC group early CD15 þ chimerism status appeared most predictive of long-term CD15 þ engraftment. After MA regimens, nearly all patients demonstrated high early CD15 þ chimerism status despite variable early CD3 þ chimerism patterns. Most in the MA group enjoyed favorable long-term CD15 þ engraftment, thus clouding the prognostic significance of early CD3 þ /CD15 þ chimerism patterns for this subgroup. For nearly all patients undergoing HSCT for FA/other marrow failure, high early CD15 þ donor chimerism was observed regardless of conditioning intensity. This observation is likely due, at least in part, to a more favorable environment for donor myeloid engraftment in this population. Nearly all of these patients enjoyed successful longterm CD15 þ chimerism status.
Although the main focus of our analysis was on the association between early CD3 þ /CD15 þ chimerism patterns and long-term CD15 þ donor engraftment, interesting trends in long-term CD3 þ chimerism emerged. For evaluable patients with early high3/high15 status (n ¼ 59), the majority (86%) retained high (X 80%) long-term donor CD3 þ presence. For those with early low3/ low15 status (n ¼ 10), the majority (90%) continued to demonstrate low, long-term donor CD3 þ chimerism. Interestingly, although nearly all with early low3/high15 status (n ¼ 24) succeeded, only 58% converted to high long-term donor CD3 þ chimerism.
Although this retrospective analysis was not able to discern a biological explanation for the prognostic dominance of early myeloid engraftment in this NMD transplant population, its finding may not be surprising. If stable, mixed hematopoietic chimerism (commonly observed following HSCT for NMD) is presumed to stem from bi-directional, T-cell immune tolerance, then earliest myeloid donor percentages may simply declare a relative 'set-point.' Deviation from such a 'set point' may not be expected in a system where neither recipient-nor donor-derived hematopoiesis enjoys an inherent proliferative advantage and in which bi-directional immune tolerance is ultimately achieved under the cover of prolonged immunosuppression. Thus, our findings might support the clinical decision to reduce immune suppression in patients who demonstrate unfavorable early donor myeloid engraftment, with the hope that ensuing allo-reactivity will be unidirectional and lead to the selective advantage of donor-derived hematopoiesis within the marrow environment.
In this study, several constraints and assumptions informed our definitions and analytic criteria. First, the use of binary early chimerism status ('high' or 'low') to define subgroups for analysis was based on both observed chimerism results and cohort size limitations. With increasing cohort size, we may be able to identify additional strata for analyses. Second, the term 'late' was applied to a chimerism value obtained on or after day þ 90. As our institution only began routine, clinical T-lymphoid fraction chimerism analysis in May 2009, we were not able to analyze prior HSCT for NMD using this model. Using the time-point of day þ 90 therefore allowed analysis of a maximal population for 'longterm' chimerism outcomes. The median time to 'late' chimerism assessment was 365 days, when the majority of patients are no longer receiving systemic immunosuppressive therapy. Even so, we analyzed the cohort's subset that was off immunosuppression at last CD15 þ chimerism reading (58 of 97, or 60%). For this subset, the distribution of patients into subgroups based on early CD3 þ and CD15 þ high/low status was nearly identical to that of the entire cohort. Furthermore, the incidence of long-term, high donor myeloid engraftment based upon subgroup assignment remained identical. Still, as the cohort 'matures', a better sense of long-term engraftment status will become available. As well, a maturing cohort will allow for assessment of the influence of GVHD in this model. Third, we chose the myelo-monocytic fraction (CD15 þ ) of PBL as the marker of long-term 'success' or 'failure'. This decision was driven by the fact that donor-derived hematopoiesis, and not donor lymphoid presence, can be presumed to provide the mechanism for disease amelioration in most NMD. In the absence of marrow and other PBL lineagespecific chimerism data for this cohort, we assumed the CD15 þ fraction to best inform the status of active, donor-derived hematopoiesis. Fourth, we set the bar for long-term 'successful' engraftment at X80% donor. This assignment is arbitrary, as the actual 'required' level of donor engraftment for functional correction of disease in the long-term varies significantly among various NMD. With a larger, more mature cohort, nuanced assessment of long-term CD15 þ values (and graft stability) may become possible. Fifth, this cohort represents a diverse patient population with respect to underlying disease, conditioning strategies and allograft sources. With increasing numbers, better prognostic significance of early chimerism patterns may be discerned for select groups of NMD patients. Finally, although it might be optimal to evaluate chimerism patterns among other lympho-hematopoietic lines besides those captured in this cohort, we were restrained by available data. Still, the monitoring of T-lymphoid and myeloid PBL fractions for post-HSCT chimerism is a common practice at many centers, making these data potentially useful to numerous clinicians.
Ultimately, our data suggest that early chimerism patterns of CD3 þ and CD15 þ PBL fractions portend long-term engraftment following HSCT for NMD. For patients with available therapies (for example, DLI), or in whom modulation of immunosuppression is feasible, these findings may guide vigilance of further chimerism monitoring and/or decisions about real-time intervention.
